Genus PLC (GNS.L)
GNS.L on London Stock Exchange
22 Jan 2018
22 Jan 2018
Change (% chg)
|72||2010||Non-Executive Independent Chairman of the Board|
|2011||Chief Executive, Executive Director|
|2013||Group Finance Director, Executive Director|
|2013||Chief Scientific Officer and Head of Genus R&D|
|2014||Group General Counsel & Company Secretary|
|2017||Group Human Resources Director|
|2013||Chief Operating Officer - Genus PIC|
|2012||Chief Operating Officer - Genus Asia|
|2017||Chief Operating Officer, Genus ABS Dairy|
|2008||Senior Non-Executive Independent Director|
|2017||IR Contact Officer|
|Mr. Robert A. Lawson, (Bob) serves as Non-Executive Independent Chairman of the Board of Genus PLC. He has significant experience of leading international businesses, including through operational and culture changes, and a deep understanding of listed companies and corporate governance. Career Bob’s executive career spanned several UK and continental groups, including ten years as Chief Executive of Electrocomponents plc and three years as Managing Director of Vitec Group plc. He was appointed Non-Executive Chairman of Eurocell plc in January 2015 and retired as Chairman of the Federation of Groundwork Trusts in November 2015. Bob retired as Non-Executive Chairman of Barratt Developments plc in November 2014.|
|Mr. Karim Bitar serves as Chief Executive, Executive Director of Genus PLC. He has extensive experience of leading international, science-based organisations. His strategic review of Genus in 2012 resulted in a new vision, strategy, structure and core values. He has a BSc in Biochemistry from the University of Wisconsin and an MBA from the University of Michigan. Prior to joining Genus, Karim worked for more than 15 years for Eli Lilly and Company, where he was President of Lilly Europe, Canada and Australia. An ex- McKinsey and Company consultant, he also held management roles at Johnson and Johnson, and the Dow Chemical Company.|
|Mr. Stephen Wilson serves as Group Finance Director, Executive Director of Genus PLC. He has worked in France and the US and has wide-ranging experience of mergers and acquisitions, financing, strategy and investor relations. He is a Fellow of the Chartered Institute of Management Accountants and holds a degree in Mathematics from the University of Cambridge. Career Stephen was previously Executive Vice President and Chief Financial Officer of Misys plc. Prior to Misys, he spent 25 years at IBM, in roles encompassing finance, business development and change programmes. He was a Non-Executive Director of Xchanging plc, where he chaired the Audit Committee until its acquisition by CSC in May 2016.|
|Dr. Jonathan Lightner serves as Chief Scientific Officer and Head of Genus R&D of Genus PLC. He is a world-renowned quantitative molecular geneticist with expertise spanning inter-related fields such as molecular biology, analytical chemistry and ‘omic’ technologies. He also has extensive regulatory and commercial experience. He holds a Masters in Systems Engineering from Iowa State, an MBA from the University of Iowa and a Doctorate in Plant Physiology from the Institute of Biological Chemistry at Washington State University. Career Jonathan joined Genus in 2013 from Pioneer Hi-Bred International Inc, a DuPont business, where he led a global team focused on genetic solutions to enhance agricultural productivity. His other leadership roles with DuPont Pioneer included Senior Research Director for Trait Characterization within Hi-Bred International. Jonathan’s previous experience included three years with Exelixis as Director of Biochemical Genomics.|
|Mr. Dan Hartley serves as Group General Counsel & Company Secretary of Genus PLC. He has significant experience in multi-jurisdictional patent litigation, mergers and acquisitions, patent licensing and managing product life cycles in complex areas. He holds degrees in science and law. Career Dan joined Genus from Shire plc, where he was Senior Vice President and International Counsel. Dan joined Shire in 2002, after a number of years in private practice, and worked in increasingly senior and global roles in the UK and the US.|
|Ms. Angelle Rosata serves as Group Human Resources Director of the company. Angelle combines commercial acumen with her broad expertise in resourcing, talent and succession, leadership development, and H&S. Her strategic planning skills and pragmatism help to align the Group’s people agenda with its business needs. Angelle holds a Masters in Human Resource Development from Vanderbilt University. Angelle joined Genus PIC in September 2013 as HR Director, following more than 20 years in the healthcare sector. She developed and delivered PIC’s people strategy, before being appointed HR Director for Genus ABS. Angelle was appointed Group HR Director and a member of GELT on 1 July 2017.|
|Mr. Bill Christianson serves as Chief Operating Officer - Genus PIC of Genus PLC. He has spent his whole career at the intersection of agriculture and biotechnology. As a result, he brings a unique blend of deep industry knowledge and extensive commercial and global experience to Genus. He holds doctorates (DVM and PhD) in Veterinary Medicine from the University of Minnesota. Career Bill has worked for the business since 1993, when he joined as Manager of Veterinary R&D, based in the US. He subsequently worked in a range of operational roles spanning Europe, South America and the US, before being appointed as General Manager of PIC North America in 2007. He led the combined ABS and PIC business across the Americas from 2010, before becoming Chief Operating Officer of Genus PIC in 2012.|
|Mr. Jerry Thompson serves as Chief Operating Officer, Genus Asia of Genus PLC. He is a natural entrepreneur and has brought his deep industry knowledge, commercial skills and international experience to develop the business in countries as diverse as the UK, Russia and China. He has helped the Company establish and grow its business in new markets, particularly those in Central and Eastern Europe and Asia. Career Jerry has worked for PIC and subsequently Genus for more than 20 years. He joined as a graduate in the UK, subsequently working in both Siberia and Romania before taking on leadership of PIC in Central and Eastern Europe. In the following years, he led PIC Europe before becoming Regional Director for PIC and ABS in Russia & Asia Pacific and subsequently Chief Operating Officer for Genus Asia. In July 2016, he became Chief Operating Officer for Genus ABS Beef.|
|Dr. Nate Zwald serves as Chief Operating Officer, Genus ABS Dairy of Genus PLC. Nate brings deep dairy genetics expertise, a strong commercial focus and a passion for people development. He grew up on the Bomaz dairy farm in the US, which has produced high-ranking industry and ABS sires, before studying at the University of Wisconsin. Here, he obtained a degree in Dairy Science, an MBA and a PhD (focused on the genetic evaluation of health traits in dairy cattle). Nate joined Genus in January 2017 after 15 years at Alta Genetics. This included being Alta’s Advantage Program Manager, in which he redesigned progeny testing in partner herds. For his final ten years with the company, Nate led Alta’s successful US business as General Manager. Nate has a strong dairy industry network and sits on the board of the Council on Dairy Cattle Breeding and is Vice President of the National Association of Animal Breeders.|
|Ms. Lysanne Gray serves as Non-Executive Director of the Company, since 1 April 2016. Lysanne has significant experience of risk management, audit, business operations, acquisitions and disposals, and corporate governance, gained within the food sector. She is a Chartered Accountant. Lysanne is Financial Controller at Unilever plc and Unilever NV. Prior to this she was Chief Auditor, working closely with Unilever’s Audit Committee, and before that Chief Financial Officer of Unilever’s global food service business. She has also held a number of other senior operational and financial positions within Unilever.|
|Prof. Duncan Maskell is no longer Non-Executive Director of Genus PLC effective from November 2018. He has co-founded several biotech companies and has extensive experience of commercialising science and innovation. He is also an experienced scientific adviser to companies, using his broad perspective on life sciences. Career Duncan is Senior Pro-Vice Chancellor (‘PVC’) of the University of Cambridge, where he and the four other PVCs are responsible for the University’s strategy and policy development. He was previously Head of the School of the Biological Sciences at the University, where he led research on infectious diseases of livestock and people.|
|Mr. Lykele Van der Broek serves as Non-Executive Director of Genus PLC. He has vast experience of growing companies and working in agricultural businesses throughout the world, including in emerging markets. Career Lykele retired as a Member of the Board of Management of Bayer CropScience, a division of Bayer AG, in 2014, being responsible for the commercialisation of innovative agricultural products and services globally. Prior to this, he held senior international roles including the Head of Bayer CropScience’s BioScience division and President of the Bayer HealthCare Animal Health division.|
|Mr. Nigel Turner serves as Senior Non-Executive Independent Director of Genus PLC. Nigel has substantial experience of international business and corporate finance. Career Nigel was Chairman of Numis Securities Ltd and Deputy Chairman of Numis Corporation plc from December 2005 to November 2007. Prior to this he was Vice Chairman of ABN AMRO’s Wholesale and Investment Bank, having joined in 2000 from Lazard, where he was a Partner for 15 years and sat on its Supervisory Board. Nigel is a Non-Executive Director of Croda International plc.|
|Name||Fiscal Year Total|
As Of 30 Jun 2017
- 3 Healthcare Stocks With More Downside Than Upside? Shire PLC, Alliance Pharma plc And Genus plc
- AstraZeneca plc, Smith & Nephew plc And Genus plc: Buy, Sell Or Hold?
- GlaxoSmithKline plc, Genus plc And Alliance Pharma plc: 3 Of The Best Health Care Stocks?
- Does Sepura Plc Offer More Value Than Genus plc & SDL plc After A 24% Rally?
- Is AstraZeneca plc A Better Buy Than BTG plc, Dechra Pharmaceuticals plc And Genus plc?
- Are Genus plc And Dechra Pharmaceuticals plc Better Buys Than GlaxoSmithKline plc?